Otsuka is buying Visterra, a US clinical-stage biotech firm, in a deal worth $430m as it looks to increase efficiencies in drug discovery and research into kidney and other diseases. Visterra’s Hierotope platform, which specialises in precision antibody-based therapies, is expected to become a "drug creation engine" for Otsuka. It uses computational and experimental technologies to develop treatments that are said to bind to and modulate hard-to-treat diseases and has a pipeline targeting kidney diseases, cancer, chronic pain and infectious diseases. The deal is expected to complete by end the end of September.
Otsuka is buying Visterra, a US clinical-stage biotech firm, in a deal worth $430m as it looks to increase efficiencies in drug discovery and research into kidney and other diseases. Visterra’s Hierotope platform, which specialises in precision antibody-based therapies, is expected to become a "drug creation engine" for Otsuka. It uses computational and experimental technologies to develop treatments that are said to bind to and modulate hard-to-treat diseases and has a pipeline targeting kidney diseases, cancer, chronic pain and infectious diseases. The deal is expected to complete by end September.